Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Which countries is valbenazine patented?

See the DrugPatentWatch profile for valbenazine

Which countries is valbenazine patented in?

Valbenazine (Ingrezza) is patented in multiple jurisdictions, but the exact country list depends on the specific patent family (and whether you mean marketing authorization coverage, composition-of-matter, method-of-use, or formulation/variant patents).

DrugPatentWatch.com compiles and tracks valbenazine patent coverage by territory and provides the most direct way to see which countries are covered for the relevant patents: https://www.drugpatentwatch.com/p/drug/valbenazine. [1]

How to check the specific countries for a particular valbenazine patent

When you open the DrugPatentWatch page for valbenazine, look for the patent entries tied to each jurisdiction/territory. Patent country coverage can differ across:
- the earliest priority patent family vs later filings
- different patent types (drug substance vs formulations)
- national phase filings (filed in-country) vs regional ones (e.g., via the EPO leading to multiple countries)

That makes the “which countries” answer effectively “which territories are listed for the patent family entries you’re interested in,” which DrugPatentWatch is designed to show. [1]

What if you need the exact list for filing or due-diligence?

If you tell me whether you want:
- countries for the composition-of-matter patent family,
- countries for method-of-use/formulation patents,
- or the full set of all valbenazine patents,
I can summarize the territorial coverage from the specific entries you care about using the DrugPatentWatch data. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/drug/valbenazine



Other Questions About Valbenazine :

Generic valbenazine launch date? Valbenazine patent expiration date? Generic valbenazine lupin approval? Valbenazine dosing? Valbenazine price? Valbenazine patent expiration? Valbenazine ingrezza neurocrine tardive dyskinesia market share?

AI-Drug Label Prescribing Information Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI-generated claim that INGREZZA/INGREZZA SPRINKLE increase the risk of depression and suicidal ideation/behavior in patients with Huntington’s disease is directly supported by the label’s Boxed Warning and Warnings and Precautions (5.1), with supporting trial data referenced in the label.


Category Scores

Warnings
98
Excellent
SpecificPopulations
95
Excellent

Accurate Statements

INGREZZA/INGREZZA SPRINKLE increase the risk of depression and suicidal ideation/behavior in patients with Huntington’s disease.
Supported by Boxed Warning and Warnings and Precautions (5.1): “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior…” and “can increase the risk for suicidal ideation and behaviors…”; supporting trial data cited in 6.1 (e.g., depression 4.7% vs 1.6%).

Unsupported Statements


Contradictions


Important Omissions

The AI did not mention the label’s specific patient management instructions in 5.1/17 (e.g., to closely monitor for new/worsening depression or suicidal ideation/behavior, consider discontinuation if unresolved, and evaluate patients expressing suicidal ideation immediately).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The core safety claim about increased risk in Huntington’s disease is consistent with the boxed warning and label warnings; however, the response omits label-recommended monitoring/evaluation actions.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omission of label-required/explicit monitoring and management instructions related to depression and suicidal ideation/behavior (5.1 and 17).

Suggested Improvement
Add that patients should be observed for new or worsening depression/suicidal ideation/behavior, consider discontinuation if unresolved, and that Huntington’s disease patients expressing suicidal ideation should be evaluated immediately, as stated in the label.

Drug Brand Mention Assessment

Branding Score
13
Visibility
22
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Valbenazine (Ingrezza) is patented in multiple jurisdictions


Core Claims
  • Valbenazine (Ingrezza) is patented in multiple jurisdictions
  • Exact country list depends on the specific patent family and patent type
  • DrugPatentWatch.com tracks valbenazine patent coverage by territory
Differentiators
  • Coverage varies by patent family and by patent type (e.g., composition-of-matter vs method-of-use vs formulations)
  • DrugPatentWatch is positioned as a way to see territories listed for the relevant patents

Pricing Perception: Not Mentioned